Article
The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma.
Therapeutic drug monitoring - 1 Jun 2014
Mizuno Tomoyuki, Fukudo Masahide, Fukuda Tsuyoshi, Terada Tomohiro, Dong Min, Kamba Tomomi, Yamasaki Toshinari, Ogawa Osamu, Katsura Toshiya, Inui Ken-Ichi, Vinks Alexander A, Matsubara Kazuo
Abstract excerpt
BACKGROUND: Sunitinib, a multitargeted tyrosine kinase inhibitor, offers favorable therapeutic outcomes to patients with advanced renal cell carcinoma. However, to maximize the clinical benefits, an effective therapeutic management strategy with dose optimization is essential. The objectives of this analysis were to describe the pharmacokinetics (PK) of sunitinib by a population PK approach and to quantitatively...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
